The digital transformation has reached our health. The Health meets Future Summit takes the increasing digitalization of the health sector into due account and is dedicated to innovations in medicine, the pharmaceutical industry, life sciences and biotech. The summit highlights current findings from research and development as well as new digital business models and their growth potentials. International masterminds and decision-makers will discuss key questions regarding the digital transformation on the highest level.
- Principles and frameworks: What are the key drivers of the transformation and what kind of framework does the digital healthcare market need?
- Data analytics and artificial intelligence: How can we utilize and monetize healthcare data and build data-driven business models?
- Transforming the patient experience: What are the most innovative and disruptive topics in the internet of you?
The conference language is English.
The hashtag for the conference is #HealthSummit.
The conference starts at 9.30 a.m. and ends at around 4.30 p.m. The final conference program is expected to be available as PDF download at the beginning of May.
If you are interested in participating in the Health meets Future Summit as a partner, please contact the person below.
Dr. Gunjan Bhardwaj
Founder and CEO, Innoplexus AG
Dr. Gunjan Bhardwaj, Founder and CEO of Innoplexus AG, a leading global AI champion with more than 80 patent applications in Artificial Intelligence, Machine Learning, and Blockchain technologies. Gunjan himself is the author of 12 patent applications. He has authored several publications in the Harvard Business Review, MIT Sloan Review, the Journal of Tumor Medicine and Prevention, the Journal of Service Research and the International Journal of Innovation Management, as well as the book Branding in Emerging Markets. He regularly publishes in Forbes, Pharma forum and other blogs. He appeared as a keynote speaker at various international life science events in healthcare.
Dr. Philipp Diesinger
Head of Global Data Science, Boehringer Ingelheim
Dr. Diesinger is a passionate data scientist who firmly believes that data-driven scientific problem solving will significantly transform industries and economies on a large scale.
Dr. Diesinger holds a PhD in theoretical physics and started his career as a data scientist in 2009 as a researcher at the Massachusetts Institute of Technology. From 2012, he worked for different companies and startups and joined with SAP Global Data Science Consulting in 2014. At SAP, he developed smart data science solutions for globally operating customers and scaled the data science team’s life science engagements.
Dr. Diesinger joined with Boehringer Ingelheim in November 2015 as Global Head of Data Science and has since been leading and developing the company’s data science capabilities following a quant-level approach driven by the philosophy that the impact of data science is maximized through bright minds and scaled through technology. The artificial intelligence solutions Dr. Diesinger and his team have been working on enabled Boehringer Ingelheim to adopt industry leading positions in key areas.
Prof. Dr. Michael Forsting
Director, Institute of Diagnostic and Interventional Radiology and Neuroradiology, Essen University Hospital
CEO, Rodenstock Group
Anders Hedegaard was born in 1960 and is a Danish citizen.
Anders Hedegaard is the CEO of the Rodenstock Group, a global leader in eye health innovation and manufacturer of ophthalmic lenses and frames.
Anders has a Master of Science in Chemical Engineering from the Technical University of Denmark.
From 1991 to 2000 he worked at Novo Nordisk A/S in various marketing and management roles with increasing responsibility. In 2000, Anders was appointed Group Vice President and member of the executive group management in Foss A/S. From 2002 to 2007 he was Executive Vice President, Business Operations & International Marketing at ALK-Abelló A/S. From 2007 to 2014, Anders was CEO of the listed Danish biotechnology company Bavarian Nordic A/S.
Before joining the Rodenstock Group, Anders served as the President and CEO of GN Hearing, one of the world’s leading manufacturers of hearing aids.
Anders brings a unique set of capabilities and values to the executive manage-ment within global leadership, marketing and sales.
Leif Pedersen is a seasoned software industry executive at Dassault Systèmes with more than 25 years of product and marketing experience supporting multiple vertical markets and a proven track record of building high-performance teams. Before joining BIOVIA as CEO, Mr. Pedersen served as executive vice president at Innovative Interfaces, senior vice president of marketing, product management and corporate development at Accelrys (now BIOVIA), and vice president at Siemens and at UGS managing business strategies. Prior to UGS, Mr. Pedersen held executive leadership positions with Vignette Corp., Novell Inc., Computer Associates and Oracle Corporation.
Member of the Executive Board, BDI e.V.
Iris Plöger is a member of the Executive Board at the Federation of German Industries (BDI), where she is responsible for digitalisation, innovation, healthcare, law, competition and consumer policy. Until 2017, she headed the department for digitalisation, innovation and healthcare at BDI. Beforehand, she worked as an expert for industrial property rights, data protection, competition and state aid law in BDI’s law department. Iris Plöger started her career in an international corporate law firm. Throughout the years, she acquired a broad international working experience e. g. in Hong Kong, New York, Los Angeles, Sydney and Brussels.
Managing Director, Health Angels GmbH
Karin studied communications science and graduated from the German School of Journalism in Munich, Germany. In 1997 she founded the strategic publication planning agency pluspool, which she brought to TBWA in 2010. After three and a half years as Managing Director at TBWA Germany, she then transferred to greyhealth group, where she spent four years as CEO. Since 2018, she has been the managing director of health angels, the healthcare agency within the Hirschen Group. Karin brings with her a long list of international clients such as Pfizer, Roche, Bayer, Olympus, GE Healthcare, Santen, Ipsen, Merck, Fresenius Kabi, Janssen and Colgate, to name just a few. Her fields of expertise range from andrology and virology to blockbuster brands and ultra rare diseases. For her, healthcare communication has to be unusual, challenging, fascinating, unmatched, grandiose and, above all, logical. Because in the end, it has to help people while changing the way they think.
Dr. Axel Schumacher
Founder & Chief Scientific Officer, Shivom
Dr. Axel Schumacher who has over 25 years’ experience in the field of genetics, epigenetics, aging & longevity; and is the Founder & Chief Scientific Officer of Shivom, a data-driven next generation precision-medicine company. Shivom’s platform aims to be the largest genomic & healthcare data-hub on the planet, allowing the world’s population to have their genome sequenced and securely stored with the help of blockchain technology. Axel is also experienced in exploring strategic opportunities in the fields of precision medicine, multi-omics, digital health, genomics data analytics, and complex diseases. He works on translating scientific discoveries into practical applications to help understand, treat, and prevent complex disorders, but also to promote cutting-edge technologies that might transform healthcare and the way we age. Axel is also a member of the Blockchain Research Institute in Toronto. He holds a Ph.D. in Human Genetics from the University of Cologne/Germany.
Prof. Dr. Mario Voigt
Member of the Thuringian state parliament; Professor of Digital Transformation and Politics, Quadriga Hochschule Berlin
Mario Voigt studied Political Science, Modern History and Public Law in Jena, Bonn and Charlottesville (USA). After that he did his doctorate at the TU Chemnitz. His professional posts were SIEMENS European Union Affairs Brussels, the Konrad Adenauer Foundation in Washington DC, Blueberry Consulting Jena and Analytik Jena AG.
In 2009 and 2014 he was elected as a direct candidate of his constituency in the Saale-Holzland-Kreis in the Thuringian state parliament. Since 2017, Voigt has been teaching and researching in addition to his political mandate as Professor of Digital Transformation and Politics at the Quadriga Hochschule Berlin.
Dr. Stefan Weiss
Business Innovation Consultant, Zühlke Group
Dr. Stefan Weiss is Business Innovation Consultant at the Zühlke Group in Eschborn, Germany. He has a broad background in Neuroscience (PhD, Helmholtz Center Munich) combined with a profound expertise in economics and innovation management (MBA, Collège des Ingénieurs). Before joining Zühlke, Stefan shaped the future of Healthcare and Life Sciences at the Innovation Center of Merck KGaA. He is passionate about the digitalization of the Pharma- and MedTech Industry with innovative solutions and business models by applying his scientific and economic expertise. At Zühlke, he extends technical excellence with domain-specific insights and thereby strengthens the partnerships with Pharma- and MedTech customers.
Speakers from last year (extract)
Dr. Boris Adryan
Chief Digital Officer / Expert for IoT & Data Analytics, Merck KGaA
Dr. Boris Adryan is a molecular biologist by training, with about 50 peer-reviewed publications in the life sciences. From 2008 to 2016 he was a Royal Society research group leader for computational genomics at the University of Cambridge, where he also taught data science and machine learning in an interdisciplinary degree programme. From 2014 his interests shifted to technology and connected products. In the meantime, Dr. Adryan has become an internationally renowned expert for IoT and M2M, and he is the lead author of “The Technical Foundations of IoT” (Artech House, Boston/London). After a short stint as Head of IoT & Data Analytics at Zühlke Engineering GmbH, he is now acting as expert and consultant within the Chief Digital Office at chemical and pharmaceutical company Merck KGaA.
Managing Director, HMG Systems Engineering GmbH
Herna Muñoz-Galeano has over 25 years of experience in specification, development, integration and management of complex engineering systems. Since 1998, Herna has been an independent entrepreneur with a special interest in transforming science into innovative products and systems. She also has knowledge of standardization at ITU, ETSI and IEEE. She has perfected the methods which optimize the development process, including integration and testing processes, for breakthrough complex technical systems. By applying the “functional anatomy” method, all projects have been completed within the given time frame and budget Herna’s way of working is analytic and systematic and has made her who she is today. Respect, openness and trust are very important to her. Her employees and customers value her fast and logical judgment as well as her reliability and social competence. She is clientservice oriented and is always open for new challenges. Due to her international background, Herna Muñoz-Galeano speaks English and German fluently and Spanish is her native language. She has implemented projects in Germany, Sweden, Spain, the Netherlands, the United Kingdom and Brazil. Herna Muñoz-Galeano holds a master’s degree in Electronics Engineering from the Universidad Distrital Francisco José de Caldas in Bogotá, Colombia, and a master’s degree in Computer Science from the Friedrich-Alexander-University in Erlangen-Nuernberg, Germany. On 29th April 2016, Herna Muñoz-Galeano was awarded the Career Award “Engineer PowerWoman 2016” by the Deutsche Messe AG at the Hannover Messe. Since 1998, Herna has been an independent entrepreneur and managing director of HMG Systems Engineering GmbH, which emerged in 2014 from the merger of two other companies established by Herna. HMG Systems Engineering GmbH was awarded in 2016 as one of the Top 100 (top100.de) most innovative SMEs in Germany.
Professor Dr. Yoshiyuki Sankai
CEO and President, CYBERDYNE, INC., Professor Dr., University of Tsukuba, Program Manager, ImPACT, promoted by Cabinet Office, Government of Japan
Yoshiyuki Sankai is a professor and Executive Research Director at the Center for Cybernics Research, University of Tsukuba; the President and CEO of CYBERDYNE, INC.; and a Program Manager of the Impulsing Paradigm Change through Disruptive Technologies (“ImPACT”) program, which was initiated by the Council for Science, Technology and Innovation (“CSTI”) of the Cabinet Office in Japan. He is a fellow of the Robotics Society of Japan (“RSJ”) and the Society of Instrument and Control Engineers (“SICE”) . He also served as Chairman and an Executive Board Member of Advanced Robotics. He is a member of Global Future Council on Human Enhancement of the World Economic Forum.
He has received numerous awards, including: The 2005 World Technology Award (World Technology Network), The 2012 Capek Award (INNOROBO), The 2014 Technology Pioneer (World Economic Forum), Gold Prize of 2014 Edison Awards, DealWatch Awards 2013 IPO of the Year (Thomson Reuters), DealWatch Awards 2014 Innovative Equity Deal of the Year (Thomson Reuters), The 2016 DIA Japan Outstanding Contribution to Health Award, the 7th Robot Award (Ministry of Health, Labour and Welfare award), and the Prime Minister’s Award (the third Nippon Venture Awards) in 2017.